JP Morgan Chase
PRLD icon

JP Morgan Chase’s Prelude Therapeutics PRLD Stock Holding History

JP Morgan Chase’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.7K Buy
13,538
+13,476
+21,735% +$58.7K ﹤0.01% 6297
2026
Q1 		$190 Hold
62
– – ﹤0.01% 7255
2025
Q4 		$180 Sell
62
-3,817
-98% -$6.44K ﹤0.01% 7169
2025
Q3 		$5.58K Buy
3,879
+1,930
+99% +$1.93K ﹤0.01% 6754
2025
Q2 		$1.58K Sell
1,949
-21,831
-92% -$18.9K ﹤0.01% 6569
2025
Q1 		$18.3K Sell
23,780
-37,369
-61% -$34.9K ﹤0.01% 6172
2024
Q4 		$78K Buy
61,149
+55,183
+925% +$73.2K ﹤0.01% 5847
2024
Q3 		$12.3K Buy
5,966
+106
+2% +$491 ﹤0.01% 6331
2024
Q2 		$22.3K Sell
5,860
-387
-6% -$1.57K ﹤0.01% 6106
2024
Q1 		$29.6K Sell
6,247
-3,133
-33% -$12.2K ﹤0.01% 6119
2023
Q4 		$40.1K Sell
9,380
-7,973
-46% -$24.3K ﹤0.01% 6062
2023
Q3 		$53.6K Buy
17,353
+8,014
+86% +$30.1K ﹤0.01% 5782
2023
Q2 		$42K Buy
9,339
+7,945
+570% +$47.5K ﹤0.01% 5757
2023
Q1 		$8K Buy
1,394
+97
+7% +$592 ﹤0.01% 6170
2022
Q4 		$8K Sell
1,297
-1,154
-47% -$7.39K ﹤0.01% 6084
2022
Q3 		$16K Buy
2,451
+418
+21% +$2.82K ﹤0.01% 5865
2022
Q2 		$11K Sell
2,033
-7,231
-78% -$36.8K ﹤0.01% 6015
2022
Q1 		$64K Buy
9,264
+2,040
+28% +$18.7K ﹤0.01% 5700
2021
Q4 		$91K Buy
7,224
+205
+3% +$3.33K ﹤0.01% 5725
2021
Q3 		$220K Buy
7,019
+130
+2% +$4.21K ﹤0.01% 5178
2021
Q2 		$197K Buy
6,889
+594
+9% +$21.1K ﹤0.01% 5255
2021
Q1 		$273K Sell
6,295
-18,201
-74% -$1.21M ﹤0.01% 5018
2020
Q4 		$1.75M Buy
+24,496
New +$1.22M ﹤0.01% 3570

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

JP Morgan Chase's PRLD Position: Q2 2026 in Review

JP Morgan Chase increased its Prelude Therapeutics (PRLD) stake by 21,735% in Q2 2026, buying an estimated $58.7K and bringing the position to 13,538 shares worth $66.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6297.

JP Morgan Chase first reported a position in PRLD in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.75M in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • JP Morgan Chase held 13,538 shares of Prelude Therapeutics worth $66.7K as of Q2 2026.
  • JP Morgan Chase bought 13,476 Prelude Therapeutics shares in Q2 2026, an estimated $58.7K.
  • Prelude Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6297 holding.
  • JP Morgan Chase first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Prelude Therapeutics position peaked at $1.75M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.